Who
Gianluca Fuggetta
See Remark
Company insider
Files Form 4 as: See Remark, Gain Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Mar 2023
- Last trade
- 24 Mar 2026
- Last filed
- 26 Mar 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Mar 2026filed 26 Mar 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 20 Mar 2025filed 21 Mar 2025 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 23 Mar 2023filed 27 Mar 2023 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinicmanilatimes.net · 13 Oct 2026
1 headline in the last 90 days name Gianluca Fuggetta; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.